Quantitative Brain Amyloid PET

Area of Science:

• Neurology
• Radiology
• Nuclear Medicine

Background:

• Amyloid PET imaging tracers have increased interest in quantifying brain amyloid burden in Alzheimer's disease (AD).
• Quantitative amyloid PET imaging offers potential for disease staging, theranostics, monitoring, and outcome measurement in clinical trials.
• Significant challenges hinder the widespread clinical implementation of quantitative amyloid PET imaging.

Purpose of the Study:

• To summarize discussions from a public workshop on the role of quantitative brain amyloid PET imaging in Alzheimer's disease.
• To explore the utility of quantitative amyloid PET imaging for staging, prognosis, and longitudinal assessment of AD.
• To identify key challenges and future directions for quantitative amyloid PET imaging in clinical practice.

Main Methods:

• A public workshop was cosponsored by the U.S. FDA, SNMMI, and MITA on November 17, 2022.
• Experts from academia, industry, and government agencies participated in the workshop.
• Presentations and discussions covered various aspects of quantitative amyloid PET imaging.

Main Results:

• The workshop addressed available radiopharmaceuticals for amyloid imaging.
• Methodology, metrics, and analytic validity of quantitative amyloid PET imaging were discussed.
• The application of quantitative amyloid PET imaging in disease staging, prognosis, and progression monitoring was explored, alongside existing challenges.

Conclusions:

• Quantitative amyloid PET imaging holds significant potential for Alzheimer's disease management and research.
• Addressing current challenges is crucial for the successful integration of quantitative amyloid PET imaging into routine clinical practice.
• Continued collaboration and research are needed to optimize the use of quantitative amyloid PET imaging for Alzheimer's disease.